(Q73504122)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9220290%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9220290%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

C F Pollera

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9220290%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

A Ceribelli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9220290%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

M Crecco

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9220290%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

C Oliva

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9220290%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

F Calabresi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9220290%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

publication date

1 January 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9220290%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

4 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9220290%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9220290%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9220290%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

115-121

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9220290%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1023/a:1005817024382

4 November 2019

exact match

0 references

cites work

Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study

1 reference

12 December 2020

Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine

1 reference

12 December 2020

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

12 December 2020

Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors

1 reference

12 December 2020

Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study

1 reference

12 December 2020

A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer

1 reference

12 December 2020

Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours

1 reference

12 December 2020

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study

1 reference

12 December 2020

Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine).

1 reference

12 December 2020

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia

1 reference

12 December 2020

Reporting results of cancer treatment

1 reference

12 December 2020

The calculation of received dose intensity

1 reference

12 December 2020